# Arvinas

vepdegestrant (ARV-471) is a first-in-class estrogen-receptor PROTAC approaching FDA approval for ER+ breast cancer, co-developed with Pfizer; it is the modality's lead regulatory asset and would be the first approved targeted-protein-degradation drug.

Source: https://en.bioecon.ru/companies/arvinas/
Updated: 2026-07-20

- Country: United States
- Ticker: ARVN

## Technologies

- [PROTACs (targeted protein degradation)](https://en.bioecon.ru/technology/protacs/)